The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
TIGIT inhibitors present a strong market opportunity, with numerous global players advancing in immuno-oncology. Key opportunities lie in developing and commercializing emerging therapies, especially ...
The CTLA-4 inhibitors market offers promising opportunities in cancer immunotherapy, with over 40 companies developing 50+ drugs globally. Key opportunities include leveraging synergistic combinations ...
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 ...
Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ...
Vascular Endothelial Growth Factor Inhibitor market grows 4.0% CAGR as biosimilars and personalized medicine expand ...
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results